Advertisement
Screener

MESOBLAST LIMITED (MESO) Form 6-K: Report of foreign private issuer, 2024

Add as a preferred source on Google

MESOBLAST LIMITED Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2024-12-23: Form 6-K; Period of report 2024-12-23; Description 6-K; Document a2024-12x23appendix3y2a.htm.
  • 2024-12-20: Form 6-K; Period of report 2024-12-19; Description 6-K; Document a2024-12xdaapprovesmesobla.htm.
  • 2024-12-20: Form 6-K; Period of report 2024-12-18; Description 6-K; Document a2024-12x19inclusioninnasd.htm.
  • 2024-12-09: Form 6-K; Period of report 2024-12-09; Description 6-K; Document a2024-12x10fdagrantsmesobl.htm.
FiledFormPeriod of reportDescriptionDocument
2024-12-236-K2024-12-236-Ka2024-12x23appendix3y2a.htm
2024-12-206-K2024-12-196-Ka2024-12xdaapprovesmesobla.htm
2024-12-206-K2024-12-186-Ka2024-12x19inclusioninnasd.htm
2024-12-096-K2024-12-096-Ka2024-12x10fdagrantsmesobl.htm
2024-12-046-K2024-12-036-Ka2024-12x04rexlemestrocelx.htm
2024-11-186-K2024-11-186-Ka2024-11x182024agmappendix.htm
2024-11-136-K2024-11-136-Ka2024-11x14appendix3g.htm
2024-11-016-K2024-10-316-Ka2024-11x01activitystateme.htm
2024-10-186-K2024-10-176-Ka2024-10x18annualreportnot.htm
2024-10-016-K2024-10-016-Ka2024-10x01convertiblenote.htm
2024-08-296-K2024-08-296-Ka2024-08x29annualreport.htm
2024-08-016-K2024-07-316-Ka2024-08x01activitystateme.htm
2024-07-256-K2024-07-236-Ka2024-07x24ryoncilfdaaccep.htm
2024-07-236-K2024-07-226-Ka2024-07x23clbppatientenro.htm
2024-07-106-K2024-07-096-Ka2024-07x10ryoncilfdablare.htm
2024-07-026-K2024-07-016-Ka2024-07x02ryoncilfdablafi.htm
2024-06-046-K2024-06-046-Ka2024-06x04conferenceprese.htm
2024-05-106-K2024-05-106-Ka2024-05x10ericrosesharepu.htm
2024-05-036-K2024-05-036-Ka2024-05x03ericrosesharepu.htm
2024-05-016-K2024-04-306-Ka2024-05x01activitystateme.htm
2024-04-176-K2024-04-166-Kform6-kxpressreleasecoverf.htm
2024-04-176-K2024-04-166-Kform6-kxpressreleasecoverf.htm
2024-04-176-K2024-04-166-Kform6-kxpressreleasecoverf.htm
2024-04-176-K2024-04-166-Kform6-kxpressreleasecoverf.htm
2024-03-276-K2024-03-266-Kform6-kxpressreleasecoverf.htm
2024-03-216-K2024-03-206-Ka2024-03x20appendix2aappen.htm
2024-03-156-K2024-03-146-Ka2024-03x15completionofpla.htm
2024-03-126-K2024-03-126-Ka2024-03x13fdasupportsacce.htm
2024-03-016-K2024-02-296-Ka2024-03x01hy1fy24results.htm
2024-02-296-K2023-12-316-Kmeso-20231231.htm
2024-02-216-K2024-02-156-Ka2024-02x16fdagrantsorphan.htm
2024-02-016-K2024-01-316-Ka2024-02x01appendix4c.htm
2024-01-236-K2024-01-196-Ka2024-01x22fdagrantsrarepe.htm
2024-01-166-K2024-01-166-Ka2024-01x16appendix3g3h3y.htm
2024-01-056-K2024-01-056-Ka2024-01x05adrratiochange.htm
2024-01-056-K2024-01-046-Ka2024-01x04resultsofretail.htm
Advertisement